lundi 29 septembre 2014

Second-line afatinib significantly improves progression-free survival in recurrent or metastatic head and neck cancer, phase III trial shows

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

Second-line afatinib significantly improves progression-free survival in recurrent or metastatic head and neck cancer, phase III trial shows

Aucun commentaire:

Enregistrer un commentaire